Remicade monotherapy approved for psoriatic arthritis

The monoclonal antibody, Remicade (infliximab) has been approved for use as monotherapy in the treatment of active and progressive psoriatic arthritis that has responded inadequately to disease-modifying anti-rheumatic drugs in patients where methotrexate is contraindicated or not tolerated.

Previously, Remicade was licensed only for use in combination with methotrexate to treat the condition.
The recommended dosage is 5mg/kg by intravenous infusion over a two-hour period, repeated two and six weeks after the first infusion and then every six to eight weeks.

Further information: Schering-Plough Ltd, Schering-Plough House, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW. Tel: (01707) 363636.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Sole of a foot with dry cracked skin on the heel.

New MIMS comparison table for urea-based emollients

Prescribers can now compare urea-based emollients with...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Logo of the webinar

Cow's Milk Allergy in Practice: free webinar series for UK healthcare professionals

Join us for a short webinar series offering insights...

Close up image of multicoloured capsules

MIMS antidepressants table updated

The MIMS table 'Antidepressants, a guide to switching...